MFDS Approves Rare Medicines for HIV Infection Treatment
Expanded Treatment Opportunities for Patients with the Import of Sunlenca Injection and Sunlenca Tablet
The Ministry of Food and Drug Safety announced on April 8 that it has approved the import of two rare medicines for the treatment of human immunodeficiency virus (HIV-1) infection: Sunlenca Injection and Sunlenca Tablet (lenacapavir).
HIV (human immunodeficiency virus) targets CD4+ T cells, a type of white blood cell, weakening the immune system. If left untreated, infection leads to acquired immunodeficiency syndrome (AIDS).
This drug is a selective inhibitor that targets the capsid protein of HIV-1. It suppresses HIV-1 replication by blocking entry into the cell nucleus, inhibiting viral assembly and release, and inducing the formation of abnormal capsids.
The Ministry stated that the medicine is indicated for adult patients with multidrug-resistant HIV-1 infection for whom previous antiretroviral therapies have failed and there are no other effective treatment options. It is expected to provide a new therapeutic opportunity for unmet medical needs where existing treatments are insufficient.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
The Ministry of Food and Drug Safety designated this drug as number 46 under the "Global Innovative Products Fast-Track Review System (GIFT)" and proceeded with an accelerated review to ensure its prompt introduction into clinical practice.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.